Table 2.
Overall | No Anal HPV Infection | Any Anal HPV Infection | RR (95% CI) | Anal HPV 16 Infection | RR (95% CI)a | |||||
---|---|---|---|---|---|---|---|---|---|---|
Characteristic | N | (%) | N | (%) | N | (%) | N | (%)* | ||
Total N | 266 | (100) | 14 | (5) | 252 | (95) | 31 | (12) | ||
Years since first HIV+ test | 4 | (±4) | 3 | (±2) | 4 | (±4) | 1.0 (1.0 – 1.0) | 3 | (±3) | 1.0 (0.8 – 1.1) |
Mean CD4+ level | 460 | (±253) | 381 | (±222) | 465 | (±255) | 1.0 (1.0 – 1.0) | 467 | (±256) | 1.0 (1.0 – 1.0) |
<200 | 35 | (13) | 3 | (9) | 32 | (91) | 0.95 (0·8 – 1.0) | 3 | (9) | 0.7 (0.2 – 1.3) |
200-500 | 125 | (48) | 7 | (6) | 118 | (94) | 0·98 (0.9 – 1.1) | 15 | (12) | 0.9 (0.6 – 1.4) |
>500 | 103 | (39) | 4 | (4) | 99 | (96) | 1·0 | 13 | (13) | 1.0 |
Lowest CD4 count (self-report) | 315 | (±234) | 218 | (±214) | 321 | (±234) | 1.0 (1.0 – 1.0) | 331 | (±235) | 1.0 (1.0 – 1.0) |
HIV viral load level | ||||||||||
Undetectable | 94 | (36) | 6 | (6) | 88 | (94) | 1.0 | 9 | (10) | 1.0 |
Detectable | 170 | (64) | 8 | (5) | 162 | (95) | 1.0 (1.0-1.1) | 22 | (73) | 1.2 (0.8-2.2) |
Ever taken ARVs | ||||||||||
Yes | 118 | (44) | 9 | (8) | 109 | (92) | 0.96 (0.9 – 1.0) | 9 | (8) | 0.6 (0.3 – 0.95) |
No | 148 | (56) | 5 | (3) | 143 | (97) | 1.0 | 22 | (15) | 1.0 |
Currently taking ARVs | ||||||||||
Yes | 116 | (44) | 8 | (7) | 108 | (93) | 0.97 (0.9 – 1.0) | 9 | (7) | 0.7 (0.3 – 1.04) |
No | 150 | (56) | 6 | (4) | 144 | (96) | 1.0 | 22 | (15) | 1.0 |
Years since first initiating ARV | 2 | (±2) | 3 | (±2) | 2 | (±2) | 0.99 (1.0 – 1.0) | 1 | (±1) | 0.8 (0.5 – 1.01) |
p-value, RR (95% CI) for comparison between having anal HPV 16 infection and having no anal HPV infection; p-value for categorical variable Fisher's Exact Test, from ANOVA or ranked ANOVA for continuous variables; significance of relative risks determined from general linear model likelihood ratio test.
Bold text =p-value <0.05; NE, not estimable.